Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01837121
Other study ID # ZOC-WDF-SMS
Secondary ID
Status Completed
Phase N/A
First received April 14, 2013
Last updated January 7, 2018
Start date January 2015
Est. completion date June 2017

Study information

Verified date January 2018
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to use a randomized controlled design to determine the impact of a SMS messaging intervention on the following outcomes among persons diagnosed with diabetic retinopathy in rural China.


Description:

SMS message reminder is a system which can sent re-visit information to remind the patient about the revisit time and address. The investigators can use the SMS system to find out if it is a useful to reduce the not-attended rate of the revisit appointment among the rural diabetic retinopathy patients.


Recruitment information / eligibility

Status Completed
Enrollment 237
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- all the diabetes patients who would like to join our study in 5 CREST cooperated rural hospitals.

Exclusion Criteria:

1. Both the patient and his/her caretakers don't have cellphone,or the one who has cellphone but don't know how to use the SMS function.

2. The first re-visit appointment time is outside our study period.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
the SMS reminder message
the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.

Locations

Country Name City State
China Blindness Preventment and Treatment Department, Zhongshan Ophthalmic Center Guangzhou Guangdong

Sponsors (3)

Lead Sponsor Collaborator
Sun Yat-sen University Orbis, The World Diabetes Foundation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Not-attended rate Compare the SMS patient not-attended rate with the control group to show the impact of SMS reminder on the compliance with scheduled follow-up visit up to 1.5 years
Secondary Knowledge about Diabetic retinopathy on a standardized examination Using a questionnaire about the comprehensive eye exam and Diabetic retinopathy to compare Knowledge about Diabetic retinopathy on a standardized examination between the SMS group and the control group up to 1.5 years
Secondary Presenting vision Presenting vision(Best corrected visual acuity) in the better-seeing and worse-seeing eyes of the two group up to 1.5 years
Secondary Loss of presenting vision Loss of presenting vision(Best corrected visual acuity) in better-seeing eye thought due to Diabetic retinopathy up to 1.5 years
Secondary Satisfaction with care Using a patient satisfaction questionnaire to compare satisfaction with care between the SMS group and the control group up tp 1.5 years
See also
  Status Clinical Trial Phase
Completed NCT03660345 - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME Phase 3
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Completed NCT03660371 - ILM Peeling in PDR Patients Undergoing PPV for VH N/A
Completed NCT04905459 - ARDA Software for the Detection of mtmDR
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT05022615 - Comparing 3 Imaging Systems
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT03702374 - Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy Phase 3
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Completed NCT04009980 - Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus. N/A
Completed NCT02924311 - Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
Not yet recruiting NCT06257082 - Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities N/A
Not yet recruiting NCT05452993 - Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography N/A
Withdrawn NCT02812030 - Aflibercept for Retinopathy in the Real World N/A
Completed NCT02391558 - Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography N/A
Active, not recruiting NCT02330042 - OCT Biomarkers for Diabetic Retinopathy
Active, not recruiting NCT02353923 - OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A